uniQure Balance Sheet Health
Financial Health criteria checks 5/6
uniQure has a total shareholder equity of $207.7M and total debt of $496.0M, which brings its debt-to-equity ratio to 238.8%. Its total assets and total liabilities are $831.7M and $624.0M respectively.
Key information
238.8%
Debt to equity ratio
US$495.99m
Debt
| Interest coverage ratio | n/a |
| Cash | US$617.89m |
| Equity | US$207.67m |
| Total liabilities | US$624.02m |
| Total assets | US$831.69m |
Recent financial health updates
Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02
Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Oct 24Recent updates
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 04uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
Apr 08We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings
Mar 04The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically
Feb 27Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23uniQure: Betting On Hemophilia-B Cure
Jan 18UniQure: Leading Gene Therapy Company
Nov 06These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Oct 24How We Are Playing UniQure
Oct 04Is uniQure N.V. (NASDAQ:QURE) Trading At A 48% Discount?
Sep 19Financial Position Analysis
Short Term Liabilities: QURE's short term assets ($651.9M) exceed its short term liabilities ($73.7M).
Long Term Liabilities: QURE's short term assets ($651.9M) exceed its long term liabilities ($550.3M).
Debt to Equity History and Analysis
Debt Level: QURE has more cash than its total debt.
Reducing Debt: QURE's debt to equity ratio has increased from 19.7% to 238.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: QURE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: QURE has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 1.9% each year